Skip to main content

Table 3 Summary of the switch from vaccination schemes based on the pentavalent vaccine with whole-cell pertussis component (wP) plus various combinations/presentations of IPV or OPV vaccines assessed in scenarios 1 to 4 to the hexavalent vaccine with acellular pertussis component (aP) and IPV

From: Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

  1. bOPV bivalent oral polio vaccine, IPV inactivated polio vaccine